Doane John F
Discover Vision Centers, Kansas City, Missouri 64055, USA.
Curr Opin Ophthalmol. 2004 Feb;15(1):16-21. doi: 10.1097/00055735-200402000-00004.
With the advent of interest in accommodative lenses as a solution for presbyopia and the growing baby-boomer demographic, ophthalmic surgeons will have the opportunity to provide this technology to facilitate near, intermediate, and distance vision for their patients.
At present, six corporate entities and lens designs are attempting to commercialize accommodative intraocular lens devices. One Food and Drug Administration (FDA) clinical trial has been completed and the first FDA-approved accommodating lens is available.
For the first time, ophthalmic surgeons will be able to provide a full range of visual focus in each eye of a patient to maintain binocular function while also avoiding the unwanted mesopic and scotopic visual disturbances that are experienced with monovision and multifocal lens technologies. Accommodative intraocular lenses could revolutionize not only cataract visual rehabilitation but also the surgical approach to presbyopia.
随着人们对可调节人工晶状体作为老花眼解决方案的兴趣日益浓厚，以及婴儿潮一代人口的不断增长，眼科外科医生将有机会提供这项技术，以帮助患者实现近、中、远距离视力。
目前，有六个公司实体和晶状体设计正在尝试将可调节人工晶状体装置商业化。一项美国食品药品监督管理局（FDA）的临床试验已经完成，首个获得FDA批准的可调节晶状体已上市。
眼科外科医生首次能够在患者的每只眼中提供全范围的视觉焦点，以维持双眼功能，同时避免单眼视力和多焦点晶状体技术所带来的不必要的中间视觉和暗视觉干扰。可调节人工晶状体不仅可能彻底改变白内障视觉康复，还可能彻底改变老花眼的手术治疗方法。
